Triple‐negative breast cancer: Present challenges and new perspectives

Podo, Franca, Buydens, Lutgarde M.C., Degani, Hadassa, Hilhorst, Riet, Klipp, Edda, Gribbestad, Ingrid S., Van Huffel, Sabine, W.M. van Laarhoven, Hanneke +10 more·2010·Molecular Oncology
DOI 10.1016/j.molonc.2010.04.006

Cites (215)

Items 201–213 of 213

  1. PET Imaging of Steroid Receptor Expression in Breast and Prostate Cancer
    Geke A.P. Hospers, Frans A. Helmond, Erik F. J. de Vries, Rudi Dierckx, Erik F. J. de Vries · 2008 · Current Pharmaceutical Design
  2. What’s Positive About ‘Triple-Negative’ Breast Cancer?
    Sara Alsterlind Hurvitz, Richard S. Finn · 2009 · Future Oncology
  3. 3LBA SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC)
    Jose M Baselga, JGM Segalla, Henri Hubert Roche, A. Del Giglio, Eva Ciruelos, Sebastião Cabral Filho, P. Gomez, Ana M. Lluch, Antonio Llombart‐Cussac, F. Costa · 2009 · European Journal of Cancer Supplements
  4. Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer
    R. S. Cornells, Hans F. A. Vasen, Hanne E.J. Meijers-Heijboer, Deborah Ford, Martin van Vliet, Angela A.G. van Tilborg, Frans J. Cleton, J.G.M. Klijn, Fred H. Menko, P. Meera Khan et al. · 1995 · Human Genetics
  5. Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype
    Luís Orlando, Giuseppe Renne, Andrea Rocca, Giuseppe Curigliano, Marco Angelo Colleoni, Gianluca Severi, G. Peruzzotti, Giuseppe Viale, G. Sanna, Aron Goldhirsch et al. · 2005 · Annals of Oncology
  6. Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer
    Kai‐Keen Shiu, David S.P. Tan, Jorge Sergio Reis-Filho · 2008 · Expert Opinion on Therapeutic Targets
  7. TIde: a software for the systematic scanning of drug targets in kinetic network models
    Marvin Schulz, Barbara M. Bakker, Edda Klipp · 2009 · BMC Bioinformatics
  8. Nuclear Imaging of Hormonal Receptor Status in Breast Cancer: A Tool for Guiding Endocrine Treatment and Drug Development
    Erik F. J. de Vries, Marianne G. Rots, Geke A.P. Hospers · 2007 · Current Cancer Drug Targets
  9. Current dilemmas and future perspectives for breast cancer screening with a focus on optimization of magnetic resonance spectroscopic imaging by advances in signal processing.
    Karen L. Belkic · 2004 · PubMed
  10. On the Implementation of HealthAgents: Agent-Based Brain Tumour Diagnosis
    Magí Lluch-Ariet, Francesc Estanyol, Mariola Mier, Carla Amor Divino Moreira Delgado, Horacio González–Vélez, Tiphaine Dalmas, Montserrat Robles, Carlos Sáez, Javier Vicente, Sabine Van Huffel et al. · 2007 · Birkhäuser Basel eBooks
  11. A quantitative model of the effect of unreplicated DNA on cell cycle progression in frog egg extracts
    Jason W. Zwolak, Nassiba Adjerid, Elife Zerrin Bagci, John J. Tyson, Jill C. Sible · 2009 · Journal of Theoretical Biology
  12. Introduction: BRCA1 and BRCA2 in mammary gland development and tumorigenesis.
    Allan Bradley, Daniel J. Medina · 1998 · Journal of Mammary Gland Biology and Neoplasia
  13. This Provisional PDF corresponds to the article as it appeared upon acceptance. Copyedited and fully formatted PDF and full text (HTML) versions will be made available soon. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors
    Marilyn L. Kwan, B. Maring, Susan E. Kutner, Christine B. Ambrosone, Bette Jane Caan · 2009